Switch theme
Sign up to access all valuation multiples
Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages).
1999
829
LTM Revenue $1.5B
LTM EBITDA $506M
$16.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zhangzhou Pientzehuang has a last 12-month revenue of $1.5B and a last 12-month EBITDA of $506M.
In the most recent fiscal year, Zhangzhou Pientzehuang achieved revenue of $1.4B and an EBITDA of $483M.
Zhangzhou Pientzehuang expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zhangzhou Pientzehuang valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.5B | XXX | XXX | XXX |
| Gross Profit | $561M | $547M | XXX | XXX | XXX |
| Gross Margin | 40% | 37% | XXX | XXX | XXX |
| EBITDA | $483M | $492M | XXX | XXX | XXX |
| EBITDA Margin | 35% | 33% | XXX | XXX | XXX |
| Net Profit | $335M | $341M | XXX | XXX | XXX |
| Net Margin | 24% | 23% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Zhangzhou Pientzehuang's stock price is CNY 204 (or $28).
Zhangzhou Pientzehuang has current market cap of CNY 123B (or $17.0B), and EV of CNY 121B (or $16.7B).
See Zhangzhou Pientzehuang trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.7B | $17.0B | XXX | XXX | XXX | XXX | $0.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Zhangzhou Pientzehuang has market cap of $17.0B and EV of $16.7B.
Zhangzhou Pientzehuang's trades at 10.8x LTM EV/Revenue multiple, and 33.0x LTM EBITDA.
Analysts estimate Zhangzhou Pientzehuang's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Zhangzhou Pientzehuang and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $16.7B | XXX | XXX | XXX |
| EV/Revenue | 11.2x | XXX | XXX | XXX |
| EV/EBITDA | 33.9x | XXX | XXX | XXX |
| P/E | 41.4x | XXX | XXX | XXX |
| P/E/Growth | 3.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpZhangzhou Pientzehuang's NTM/LTM revenue growth is 12%
Zhangzhou Pientzehuang's revenue per employee for the last fiscal year averaged $1.7M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Zhangzhou Pientzehuang's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Zhangzhou Pientzehuang's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Zhangzhou Pientzehuang and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 45% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 14% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhangzhou Pientzehuang acquired XXX companies to date.
Last acquisition by Zhangzhou Pientzehuang was XXXXXXXX, XXXXX XXXXX XXXXXX . Zhangzhou Pientzehuang acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Zhangzhou Pientzehuang founded? | Zhangzhou Pientzehuang was founded in 1999. |
| Where is Zhangzhou Pientzehuang headquartered? | Zhangzhou Pientzehuang is headquartered in China. |
| How many employees does Zhangzhou Pientzehuang have? | As of today, Zhangzhou Pientzehuang has 829 employees. |
| Is Zhangzhou Pientzehuang publicy listed? | Yes, Zhangzhou Pientzehuang is a public company listed on SHG. |
| What is the stock symbol of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang trades under 600436 ticker. |
| When did Zhangzhou Pientzehuang go public? | Zhangzhou Pientzehuang went public in 2003. |
| Who are competitors of Zhangzhou Pientzehuang? | Similar companies to Zhangzhou Pientzehuang include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang's current market cap is $17.0B |
| What is the current revenue of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang's last 12-month revenue is $1.5B. |
| What is the current EBITDA of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang's last 12-month EBITDA is $506M. |
| What is the current EV/Revenue multiple of Zhangzhou Pientzehuang? | Current revenue multiple of Zhangzhou Pientzehuang is 10.8x. |
| What is the current EV/EBITDA multiple of Zhangzhou Pientzehuang? | Current EBITDA multiple of Zhangzhou Pientzehuang is 33.0x. |
| What is the current revenue growth of Zhangzhou Pientzehuang? | Zhangzhou Pientzehuang revenue growth between 2023 and 2024 was 8%. |
| Is Zhangzhou Pientzehuang profitable? | Yes, Zhangzhou Pientzehuang is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
